Skip to main content

Beijing Minhai Biotechnology Co., Ltd

Beijing Minhai Biotechnology Co.,Ltd.(referred to as “Minhai”) is a modern biotechnology enterprise specialized in vaccine R&D, production and distribution. Minhai's mission is to provide safe, stable and affordable vaccines; increase immunization coverage, reduce the incidence of infectious disease and mortality; protect human health. Minhai was founded in June 2004, with a registered capital of 500 million RMB and a total asset of 900 million RMB, at No.35 Simiao Road, Bioengineering &Pharmaceutical Industrial Park, Daxing District, Beijing, which has a leading R&D center and a modern vaccine manufacturing site composed of over 60,000 m2 GMP compliant workshops, equipped with advanced large-scale bacteria vaccine production line and virus vaccine production line. Until 2019, there are four commercialized vaccine products, including Hib conjugate vaccine, MR vaccine and DTaP-Hib vaccine and 23 valent PPSV vaccine. DTaP-Hib vaccine, which is independently developed by Minhai, is the first domestic tetravalent vaccine. There are over 20 vaccines in Minhai's pipeline (from pre-clinical trial to NDA), including 13 valent PCV, HDCV rabies vaccine, sabin IPV and PENTA etc. In the meantime of developing novel vaccines, Minhai initiated international registration and accelerated the process of export. From 2013, Minhai has started the registration of four marketed products in more than 15 countries including Uzbekistan, Pakistan, India, Russia and the Philippines, and initiated WHO prequalification preparation. Minhai is enlarging multi-angle, multi-level international collaboration, and extensively promote globalization strategy. Minhai is collaborating and competing with world class vaccine enterprises, working hard to share Minhai's safe, stable and affordable vaccines with all human beings around the world.